Cargando…

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?

Prediction of treatment response is a crucial issue in individualised treatment for cancer patients. In this context, Nassar and colleagues in the accompanying study published in the British Journal of Cancer analysed retrospectively a cohort of 62 metastatic urothelial cancer patients treated with...

Descripción completa

Detalles Bibliográficos
Autor principal: Niegisch, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029037/
https://www.ncbi.nlm.nih.gov/pubmed/31857721
http://dx.doi.org/10.1038/s41416-019-0684-2
_version_ 1783499087303147520
author Niegisch, Günter
author_facet Niegisch, Günter
author_sort Niegisch, Günter
collection PubMed
description Prediction of treatment response is a crucial issue in individualised treatment for cancer patients. In this context, Nassar and colleagues in the accompanying study published in the British Journal of Cancer analysed retrospectively a cohort of 62 metastatic urothelial cancer patients treated with immune checkpoint inhibitors and of whom not only clinical but also genomic characteristics were available. Combining molecular and clinical factors in a multivariable analysis they identified lack of visceral metastases, neutrophil-to-lymphocyte ratio (NLR) <5, and high single nucleotide variant (SNV) count (≥10) as independent predictors of treatment response.
format Online
Article
Text
id pubmed-7029037
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70290372020-12-20 Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine? Niegisch, Günter Br J Cancer Editorial Prediction of treatment response is a crucial issue in individualised treatment for cancer patients. In this context, Nassar and colleagues in the accompanying study published in the British Journal of Cancer analysed retrospectively a cohort of 62 metastatic urothelial cancer patients treated with immune checkpoint inhibitors and of whom not only clinical but also genomic characteristics were available. Combining molecular and clinical factors in a multivariable analysis they identified lack of visceral metastases, neutrophil-to-lymphocyte ratio (NLR) <5, and high single nucleotide variant (SNV) count (≥10) as independent predictors of treatment response. Nature Publishing Group UK 2019-12-20 2020-02-18 /pmc/articles/PMC7029037/ /pubmed/31857721 http://dx.doi.org/10.1038/s41416-019-0684-2 Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Editorial
Niegisch, Günter
Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
title Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
title_full Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
title_fullStr Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
title_full_unstemmed Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
title_short Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
title_sort predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029037/
https://www.ncbi.nlm.nih.gov/pubmed/31857721
http://dx.doi.org/10.1038/s41416-019-0684-2
work_keys_str_mv AT niegischgunter predictingimmunecheckpointinhibitorresponseinurothelialcarcinomaanotherstepinpersonalisedmedicine